ci 994 has been researched along with Recrudescence in 1 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| el-Beltagi, HM | 1 |
| Martens, AC | 1 |
| Dahab, GM | 1 |
| Hagenbeek, A | 1 |
1 other study available for ci 994 and Recrudescence
| Article | Year |
|---|---|
Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Disease Models, Animal; Dru | 1993 |